BBIO

In Q1 2026, BridgeBio reported total revenues of $194.5 million, exceeding forecasts, driven by U.S. Attruby net product revenue, which represented a 392% year-over-year growth, but reported an EPS of -$0.84, missing consensus estimates. The Board of Directors authorized a share repurchase program of up to $500 million. The company submitted its first of three planned NDAs to the FDA for BBP-418 in LGMD2I/R9, with NDAs for encaleret and oral infigratinib planned for 1H 2026 and Q3 2026, respectively. BridgeBio announced inducement equity grants for new employees in April and May 2026 and management participated in investor fireside chats at healthcare conferences in May–June 2026. As of May 6, 2026, the share price was $68.08, representing a 90.06% increase over the past year, but decreased by 11.9% from the beginning of 2026 to May 9, 2026.